Amylyx Will Submit ALS Drug For Approval In The Coming Months
Continues ‘As Fast As Possible’ Approach With AMX0035
After discussions with the US FDA, the company determined it can file AMX0035 based on Phase II/III results and interim Phase III data. Amylyx is sticking with its go-it-alone strategy for global commercialization.
